Contact
searchSearch
HMP Global
Login

Oncology

Featured

News
Mocertatug Rezetecan Demonstrates Encouraging Activity in Platinum-Resistant Ovarian and Endometrial Cancer
06/17/2026
Stephanie Holland
Results from the phase 1 BEHOLD-1 trial demonstrated that mocertatug rezetecan showed encouraging antitumor activity among patients with platinum-resistant ovarian cancer and advanced or recurrent endometrial cancer.
Results from the phase 1 BEHOLD-1 trial demonstrated that mocertatug rezetecan showed encouraging antitumor activity among patients with platinum-resistant ovarian cancer and advanced or recurrent endometrial cancer.
Results from the phase 1...
06/17/2026
Oncology
Quiz
Polycythemia Vera Management Pre-Survey
06/17/2026
Thank you for taking part in this brief survey. Your response will provide valuable insight into how clinicians manage polycythemia vera in clinical practice. 
Thank you for taking part in this brief survey. Your response will provide valuable insight into how clinicians manage polycythemia vera in clinical practice. 
Thank you for taking part in...
06/17/2026
Oncology
Infographic
Symptom Management Strategies in Polycythemia Vera
06/17/2026
06/17/2026
Oncology
Videos
Laying the Groundwork for Success in Polycythemia Vera Management
06/17/2026
Michael R. Grunwald, MD
Dr Michael Grunwald discusses practical patient counseling and symptom management strategies that can help support long-term disease control goals among patients with polycythemia vera.
Dr Michael Grunwald discusses practical patient counseling and symptom management strategies that can help support long-term disease control goals among patients with polycythemia vera.
Dr Michael Grunwald discusses...
06/17/2026
Oncology
Infographic
Polycythemia Vera Management and Interferons
06/17/2026
Learn more about the place of interferons in the treatment of polycythemia vera.
Learn more about the place of interferons in the treatment of polycythemia vera.
Learn more about the place of...
06/17/2026
Oncology
Videos
Interferons in Polycythemia Vera Management
06/17/2026
Lucia Masarova, MD
Dr Lucia Masarova discusses the place of interferons in the treatment of polycythemia vera, particularly in achieving hematological response and disease control​.
Dr Lucia Masarova discusses the place of interferons in the treatment of polycythemia vera, particularly in achieving hematological response and disease control​.
Dr Lucia Masarova discusses the...
06/17/2026
Oncology
Infographic
Managing Low-Risk Polycythemia Vera
06/17/2026
Review this infographic to learn more about low-risk polycythemia vera's association with ongoing disease-control challenges and available cytoreductive strategies​.
Review this infographic to learn more about low-risk polycythemia vera's association with ongoing disease-control challenges and available cytoreductive strategies​.
Review this infographic to learn...
06/17/2026
Oncology
Videos
Reassessing Risk in “Low-Risk” Polycythemia Vera
06/17/2026
Michael R. Grunwald, MD
Dr Michael Grunwald reviews the ongoing disease-control challenges associated with low-risk polycythemia vera and the cytoreductive strategies that can help address them​.
Dr Michael Grunwald reviews the ongoing disease-control challenges associated with low-risk polycythemia vera and the cytoreductive strategies that can help address them​.
Dr Michael Grunwald reviews the...
06/17/2026
Oncology
Infographic
Importance of White Blood Cell Count in Polycythemia Vera
06/17/2026
Review this infographic to learn more about leukocytosis as a risk signal in polycythemia vera and the role of durable blood count control in comprehensive risk reduction.
Review this infographic to learn more about leukocytosis as a risk signal in polycythemia vera and the role of durable blood count control in comprehensive risk reduction.
Review this infographic to learn...
06/17/2026
Oncology
Videos
Why White Blood Cell Count Matters in Polycythemia Vera
06/17/2026
Lucia Masarova, MD
Dr Lucia Masarova discusses leukocytosis as a clinically meaningful risk signal and management target in polycythemia vera and the importance of durable blood count control in reducing risk.
Dr Lucia Masarova discusses leukocytosis as a clinically meaningful risk signal and management target in polycythemia vera and the importance of durable blood count control in reducing risk.
Dr Lucia Masarova discusses...
06/17/2026
Oncology
News
Anti T-Lymphocyte Globulin Remains Standard GVHD Prophylaxis Following Unrelated Donor Transplantation
06/16/2026
Emily Estrada
Results from a phase 3 trial demonstrated that post-transplant cyclophosphamide did not achieve noninferiority to anti–T-lymphocyte globulin for overall survival following unrelated donor alloHCT in patients with high-risk myeloid...
Results from a phase 3 trial demonstrated that post-transplant cyclophosphamide did not achieve noninferiority to anti–T-lymphocyte globulin for overall survival following unrelated donor alloHCT in patients with high-risk myeloid...
Results from a phase 3 trial...
06/16/2026
Oncology

Videos

Videos
Laying the Groundwork for Success in Polycythemia Vera Management
06/17/2026
Michael R. Grunwald, MD
Dr Michael Grunwald discusses practical patient counseling and symptom management strategies that can help support long-term disease control goals among patients with polycythemia vera.
Dr Michael Grunwald discusses practical patient counseling and symptom management strategies that can help support long-term disease control goals among patients with polycythemia vera.
Dr Michael Grunwald discusses...
06/17/2026
Oncology
Videos
Interferons in Polycythemia Vera Management
06/17/2026
Lucia Masarova, MD
Dr Lucia Masarova discusses the place of interferons in the treatment of polycythemia vera, particularly in achieving hematological response and disease control​.
Dr Lucia Masarova discusses the place of interferons in the treatment of polycythemia vera, particularly in achieving hematological response and disease control​.
Dr Lucia Masarova discusses the...
06/17/2026
Oncology
Videos
Reassessing Risk in “Low-Risk” Polycythemia Vera
06/17/2026
Michael R. Grunwald, MD
Dr Michael Grunwald reviews the ongoing disease-control challenges associated with low-risk polycythemia vera and the cytoreductive strategies that can help address them​.
Dr Michael Grunwald reviews the ongoing disease-control challenges associated with low-risk polycythemia vera and the cytoreductive strategies that can help address them​.
Dr Michael Grunwald reviews the...
06/17/2026
Oncology
Videos
Why White Blood Cell Count Matters in Polycythemia Vera
06/17/2026
Lucia Masarova, MD
Dr Lucia Masarova discusses leukocytosis as a clinically meaningful risk signal and management target in polycythemia vera and the importance of durable blood count control in reducing risk.
Dr Lucia Masarova discusses leukocytosis as a clinically meaningful risk signal and management target in polycythemia vera and the importance of durable blood count control in reducing risk.
Dr Lucia Masarova discusses...
06/17/2026
Oncology
Roger Von Moos, MD
Videos
Reducing Treatment Burden in With Extended Interval Denosumab in Patients With Metastatic Bone Disease
06/16/2026
Roger von Moos, MD, discusses results from the phase 3 SAKK 96/12 REDUSE trial which demonstrated that denosumab administered every 12 weeks was noninferior to standard every-4-week dosing for preventing symptomatic skeletal events while...
Roger von Moos, MD, discusses results from the phase 3 SAKK 96/12 REDUSE trial which demonstrated that denosumab administered every 12 weeks was noninferior to standard every-4-week dosing for preventing symptomatic skeletal events while...
Roger von Moos, MD, discusses...
06/16/2026
Oncology
Enrique Ocio, MD, PhD
Videos
DREAMM-9 Final Analysis Shows Strong Efficacy With Belantamab Mafodotin Plus VRd in Newly Diagnosed Multiple Myeloma
06/16/2026
Enrique Ocio, MD, PhD, discusses final results from the DREAMM-9 trial which showed that dose-adapted belantamab mafodotin plus bortezomib, lenalidomide, and dexamethasone achieved high response rates, deep MRD-negative remissions, and...
Enrique Ocio, MD, PhD, discusses final results from the DREAMM-9 trial which showed that dose-adapted belantamab mafodotin plus bortezomib, lenalidomide, and dexamethasone achieved high response rates, deep MRD-negative remissions, and...
Enrique Ocio, MD, PhD, discusses...
06/16/2026
Oncology
Roberto Mina, MD
Videos
Teclistamab Monotherapy Improves Outcomes in Patients With Relapsed or Refractory Multiple Myeloma
06/16/2026
Roberto Mina, MD
Roberto Mina, MD, discusses results from the phase 3 MajesTEC-9 trial evaluating teclistamab monotherapy in patients with relapsed or refractory multiple myeloma.
Roberto Mina, MD, discusses results from the phase 3 MajesTEC-9 trial evaluating teclistamab monotherapy in patients with relapsed or refractory multiple myeloma.
Roberto Mina, MD, discusses...
06/16/2026
Oncology
Marlana Orloff, MD
Videos
Darovasertib Plus Crizotinib Combination Demonstrates Meaningful Clinical Benefit in Metastatic Uveal Melanoma
06/15/2026
Marlana Orloff, MD, discusses results from the phase 2 OPTIMUS-2 trial showing that darovasertib plus crizotinib significantly improved progression-free survival, response rates, and disease control compared with investigator’s choice therapy...
Marlana Orloff, MD, discusses results from the phase 2 OPTIMUS-2 trial showing that darovasertib plus crizotinib significantly improved progression-free survival, response rates, and disease control compared with investigator’s choice therapy...
Marlana Orloff, MD, discusses...
06/15/2026
Oncology
Omar Nadeem, MD
Videos
Teclistamab Achieves Deep MRD-Negative Responses in High-Risk Smoldering Myeloma
06/15/2026
Omar Nadeem, MD, discusses results from the phase 2 ImmunoPRISM trial evaluating teclistamab in patients with high-risk smoldering multiple myeloma.
Omar Nadeem, MD, discusses results from the phase 2 ImmunoPRISM trial evaluating teclistamab in patients with high-risk smoldering multiple myeloma.
Omar Nadeem, MD, discusses...
06/15/2026
Oncology
Vincent Chung, MD
Videos
Pembrolizumab and Olaparib Combination Demonstrates Signals of Activity in BRCA-Mutated Pancreatic Cancer
06/12/2026
Vincent Chung, MD, disucsses results from the phase 2 SWOG S2001 trial which demonstrated that olaparib plus pembrolizumab improved response and progression-free survival in germline BRCA1/2-mutated pancreatic cancer.
Vincent Chung, MD, disucsses results from the phase 2 SWOG S2001 trial which demonstrated that olaparib plus pembrolizumab improved response and progression-free survival in germline BRCA1/2-mutated pancreatic cancer.
Vincent Chung, MD, disucsses...
06/12/2026
Oncology

Insights From the ASCO Annual Meeting

Roger Von Moos, MD
Videos
Reducing Treatment Burden in With Extended Interval Denosumab in Patients With Metastatic Bone Disease
06/16/2026
Roger von Moos, MD, discusses results from the phase 3 SAKK 96/12 REDUSE trial which demonstrated that denosumab administered every 12 weeks was noninferior to standard every-4-week dosing for preventing symptomatic skeletal events while...
Roger von Moos, MD, discusses results from the phase 3 SAKK 96/12 REDUSE trial which demonstrated that denosumab administered every 12 weeks was noninferior to standard every-4-week dosing for preventing symptomatic skeletal events while...
Roger von Moos, MD, discusses...
06/16/2026
Oncology
Roberto Mina, MD
Videos
Teclistamab Monotherapy Improves Outcomes in Patients With Relapsed or Refractory Multiple Myeloma
06/16/2026
Roberto Mina, MD
Roberto Mina, MD, discusses results from the phase 3 MajesTEC-9 trial evaluating teclistamab monotherapy in patients with relapsed or refractory multiple myeloma.
Roberto Mina, MD, discusses results from the phase 3 MajesTEC-9 trial evaluating teclistamab monotherapy in patients with relapsed or refractory multiple myeloma.
Roberto Mina, MD, discusses...
06/16/2026
Oncology
Marlana Orloff, MD
Videos
Darovasertib Plus Crizotinib Combination Demonstrates Meaningful Clinical Benefit in Metastatic Uveal Melanoma
06/15/2026
Marlana Orloff, MD, discusses results from the phase 2 OPTIMUS-2 trial showing that darovasertib plus crizotinib significantly improved progression-free survival, response rates, and disease control compared with investigator’s choice therapy...
Marlana Orloff, MD, discusses results from the phase 2 OPTIMUS-2 trial showing that darovasertib plus crizotinib significantly improved progression-free survival, response rates, and disease control compared with investigator’s choice therapy...
Marlana Orloff, MD, discusses...
06/15/2026
Oncology
Vincent Chung, MD
Videos
Pembrolizumab and Olaparib Combination Demonstrates Signals of Activity in BRCA-Mutated Pancreatic Cancer
06/12/2026
Vincent Chung, MD, disucsses results from the phase 2 SWOG S2001 trial which demonstrated that olaparib plus pembrolizumab improved response and progression-free survival in germline BRCA1/2-mutated pancreatic cancer.
Vincent Chung, MD, disucsses results from the phase 2 SWOG S2001 trial which demonstrated that olaparib plus pembrolizumab improved response and progression-free survival in germline BRCA1/2-mutated pancreatic cancer.
Vincent Chung, MD, disucsses...
06/12/2026
Oncology
Alicia Morgans, MD
Videos
Enzalutamide Associated with Increased Cognitive Decline in in Advanced Prostate Cancer
06/12/2026
Alicia Morgans, MD, discusses results from the ARACOG trial which demonstrated that greater enzalutamide was associated with greater cognitive decline compared with darolutamide in patients with advanced prostate cancer.
Alicia Morgans, MD, discusses results from the ARACOG trial which demonstrated that greater enzalutamide was associated with greater cognitive decline compared with darolutamide in patients with advanced prostate cancer.
Alicia Morgans, MD, discusses...
06/12/2026
Oncology
Janice Mehnert, MD
Videos
Adjuvant Pembrolizumab Reduces Distant Recurrence Risk in Merkel Cell Carcinoma
06/12/2026
Janice Mehnert, MD
Janice Mehnert, MD, discusses updated phase 3 STAMP trial results showing that adjuvant pembrolizumab improved distant metastasis-free survival in patients with surgically treated Merkel cell carcinoma, while exploratory analyses suggested...
Janice Mehnert, MD, discusses updated phase 3 STAMP trial results showing that adjuvant pembrolizumab improved distant metastasis-free survival in patients with surgically treated Merkel cell carcinoma, while exploratory analyses suggested...
Janice Mehnert, MD, discusses...
06/12/2026
Oncology
Oleg Gluz, MD
Videos
Longer Docetaxel-Based Chemotherapy Associated With Improved Outcomes in High-Risk HR-Positive, HER2-Negative Breast Cancer
06/11/2026
Oleg Gluz, MD
Oleg Gluz, MD, discusses pooled analyses from the PlanB and ADAPT trials suggesting that longer docetaxel-based chemotherapy may improve outcomes in patients with high-risk HR-positive, HER2-negative early breast cancer.
Oleg Gluz, MD, discusses pooled analyses from the PlanB and ADAPT trials suggesting that longer docetaxel-based chemotherapy may improve outcomes in patients with high-risk HR-positive, HER2-negative early breast cancer.
Oleg Gluz, MD, discusses pooled...
06/11/2026
Oncology
Jamie Chaft, MD
Videos
Adjuvant Nivolumab Fails to Improve DFS Regardless of PD-L1 Status in Non-Small Cell Lung Cancer
06/10/2026
Jamie Chaft, MD
Jamie Chaft, MD, discusses results from the phase 3 EA5142 trial, part of the National Cancer Institute’s ALCHEMIST program, evaluating adjuvant nivolumab in patients with resected EGFR or ALK-negative NSCLC following standard therapy.
Jamie Chaft, MD, discusses results from the phase 3 EA5142 trial, part of the National Cancer Institute’s ALCHEMIST program, evaluating adjuvant nivolumab in patients with resected EGFR or ALK-negative NSCLC following standard therapy.
Jamie Chaft, MD, discusses...
06/10/2026
Oncology
News
Tisagenlecleucel Produces Durable Remissions in Very High-Risk B-Cell Acute Lymphoblastic Leukemia
06/10/2026
Stephanie Holland
Results from the phase 2 COG AALL1721/CASSIOPEIA trial demonstrated that tisagenlecleucel produced durable remissions in adolescent and young adult patients with high-risk B-cell acute lymphoblastic leukemia and persistent MRD during...
Results from the phase 2 COG AALL1721/CASSIOPEIA trial demonstrated that tisagenlecleucel produced durable remissions in adolescent and young adult patients with high-risk B-cell acute lymphoblastic leukemia and persistent MRD during...
Results from the phase 2 COG...
06/10/2026
Oncology
News
Asciminib Demonstrates Clinical Activity in Relapsed or Refractory Ph-Positive Acute Lymphoblastic Leukemia
06/10/2026
Stephanie Holland
Results from a retrospective real-world analysis demonstrated that asciminib produced clinically meaningful remission in adult patients with relapsed, refractory, or treatment-intolerant Ph-positive acute lymphoblastic leukemia.
Results from a retrospective real-world analysis demonstrated that asciminib produced clinically meaningful remission in adult patients with relapsed, refractory, or treatment-intolerant Ph-positive acute lymphoblastic leukemia.
Results from a retrospective...
06/10/2026
Oncology

Insights From the ESMO Congress

Stephen Freedland, MD
Videos
Enzalutamide Plus Androgen Deprivation Therapy in Biochemically Recurrent Prostate Cancer
12/02/2025
Stephen J. Freedland, MD
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses...
12/02/2025
Oncology
Brian Slomovitz, MD
Videos
Relacorilant Plus Nab-Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer
12/02/2025
Brian M. Slomovitz, MD, MS
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses...
12/02/2025
Oncology
Pasi Jänne, MD, PhD
Videos
Osimertinib Plus Chemotherapy Provides Broad Survival Benefit in EGFR-Mutant NSCLC
12/02/2025
Pasi Jänne, MD, PhD
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses...
12/02/2025
Oncology
David Goldstein, MD
Videos
Regorafenib Plus Nivolumab Fails to Improve Outcomes in Gastric or Gastroesophageal Cancer
12/02/2025
David Goldstein, MD
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses...
12/02/2025
Oncology
Sara Lonardi, MD
Videos
Dual Immunotherapy Delivers Durable Benefit in MSI-H/dMMR Metastatic Colorectal Cancer
11/13/2025
Sara Lonardi, MD
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated...
11/13/2025
Oncology
Sanjay Popat, MD, PhD
Videos
First-Line Zongertinib Demonstrates Promise in HER2-Mutated NSCLC
11/13/2025
Sanjay Popat, MD
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses...
11/13/2025
Oncology
Janice Mehnert, MD
Videos
Pembrolizumab Lowers Distant Recurrence Risk in Resected Merkel Cell Carcinoma
11/10/2025
Janice Mehnert, MD
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses...
11/10/2025
Oncology
Nima Nabavizadeh, MD
Videos
MCED Blood Test Detects Cancer Early With High Accuracy
11/10/2025
Nima Nabavizadeh, MD
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses...
11/10/2025
Oncology
Maria De Santis, MD
Videos
Addition of Durvalumab Strengthens Treatment for Patients With High-Risk Non–Muscle Invasive Bladder Cancer
11/10/2025
Maria De Santis, MD
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses...
11/10/2025
Oncology
Dean Fennell, MD, PhD
Videos
Intratumor Heterogeneity Predicts Niraparib Benefit in Relapsed Mesothelioma
11/10/2025
Dean Fennell, MD, PhD
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses...
11/10/2025
Oncology

Live Meetings

Recent News

News
Mocertatug Rezetecan Demonstrates Encouraging Activity in Platinum-Resistant Ovarian and Endometrial Cancer
06/17/2026
Stephanie Holland
Results from the phase 1 BEHOLD-1 trial demonstrated that mocertatug rezetecan showed encouraging antitumor activity among patients with platinum-resistant ovarian cancer and advanced or recurrent endometrial cancer.
Results from the phase 1 BEHOLD-1 trial demonstrated that mocertatug rezetecan showed encouraging antitumor activity among patients with platinum-resistant ovarian cancer and advanced or recurrent endometrial cancer.
Results from the phase 1...
06/17/2026
Oncology
News
Anti T-Lymphocyte Globulin Remains Standard GVHD Prophylaxis Following Unrelated Donor Transplantation
06/16/2026
Emily Estrada
Results from a phase 3 trial demonstrated that post-transplant cyclophosphamide did not achieve noninferiority to anti–T-lymphocyte globulin for overall survival following unrelated donor alloHCT in patients with high-risk myeloid...
Results from a phase 3 trial demonstrated that post-transplant cyclophosphamide did not achieve noninferiority to anti–T-lymphocyte globulin for overall survival following unrelated donor alloHCT in patients with high-risk myeloid...
Results from a phase 3 trial...
06/16/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Significantly Improves Outcomes in Heavily Pretreated Relapsed or Refractory Multiple Myeloma
06/16/2026
Emily Estrada
Results from the SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved outcomes in heavily pretreated patients with relapsed or refractory multiple myeloma.
Results from the SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved outcomes in heavily pretreated patients with relapsed or refractory multiple myeloma.
Results from the SUCCESSOR-2...
06/16/2026
Oncology
News
In Vivo CAR T-Cell Therapy Shows Encouraging Early Activity in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
06/16/2026
Emily Estrada
Results from an ongoing phase 1 trial demonstrated that LB2501 shows encouraging activity and promising safety in patients with relapsed or refractory non-Hodgkin lymphomas.
Results from an ongoing phase 1 trial demonstrated that LB2501 shows encouraging activity and promising safety in patients with relapsed or refractory non-Hodgkin lymphomas.
Results from an ongoing phase 1...
06/16/2026
Oncology
News
Gilteritinib Fails to Improve OS in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia
06/16/2026
Emily Estrada
Results from the phase 3 HOVON156/AMLSG28-18/PASHA trial demonstrated that gilteritinib did not significantly improve overall survival compared with midostaurin when combined with intensive chemotherapy in patients with newly diagnosed...
Results from the phase 3 HOVON156/AMLSG28-18/PASHA trial demonstrated that gilteritinib did not significantly improve overall survival compared with midostaurin when combined with intensive chemotherapy in patients with newly diagnosed...
Results from the phase 3...
06/16/2026
Oncology
News
Fixed-Duration Pirtobrutinib Plus Venetoclax and Rituximab Emerges as Potential New Standard in Relapsed or Refractory Chronic Lymphocytic Leukemia
06/16/2026
Stephanie Holland
Results from the phase 3 BRUIN CLL-322 trial demonstrated that pirtobrutinib plus venetoclax and rituximab significantly improved outcomes compared with venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia.
Results from the phase 3 BRUIN CLL-322 trial demonstrated that pirtobrutinib plus venetoclax and rituximab significantly improved outcomes compared with venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia.
Results from the phase 3 BRUIN...
06/16/2026
Oncology
News
Switchable Allogeneic CAR T-Cell Therapy Shows Early Promise in Relapsed or Refractory Acute Myeloid Leukemia
06/16/2026
Emily Estrada
Results from the phase 1a RevSTAR-123 study demonstrated that an investigational switchable allogeneic CD123-directed CAR T-cell therapy showed encouraging clinical activity in heavily pretreated relapsed or refractory acute myeloid leukemia.
Results from the phase 1a RevSTAR-123 study demonstrated that an investigational switchable allogeneic CD123-directed CAR T-cell therapy showed encouraging clinical activity in heavily pretreated relapsed or refractory acute myeloid leukemia.
Results from the phase 1a...
06/16/2026
Oncology
News
CD5 Inhibition Enhances Activity of T-Cell Engagers Across Tumor Types
06/16/2026
Stephanie Holland
Results from a translational study identified CD5 as a key negative regulator of T-cell engager activity and suggest that CD5 inhibition may enhance responses to multiple CD3-engaging therapies.
Results from a translational study identified CD5 as a key negative regulator of T-cell engager activity and suggest that CD5 inhibition may enhance responses to multiple CD3-engaging therapies.
Results from a translational...
06/16/2026
Oncology
News
Talquetamab-Based Regimens Improve Survival in Relapsed or Refractory Multiple Myeloma
06/16/2026
Stephanie Holland
Results from the phase 3 MonumenTAL-3 trial demonstrated that talquetamab-based regimens significantly improved outcomes compared with daratumumab plus pomalidomide and dexamethasone in relapsed or refractory multiple myeloma.
Results from the phase 3 MonumenTAL-3 trial demonstrated that talquetamab-based regimens significantly improved outcomes compared with daratumumab plus pomalidomide and dexamethasone in relapsed or refractory multiple myeloma.
Results from the phase 3...
06/16/2026
Oncology
News
Tafasitamab Plus Lenalidomide and R-CHOP Emerges as Potential New Standard in High-Risk Diffuse Large B-Cell Lymphoma
06/15/2026
Stephanie Holland
Results from the phase 3 frontMIND trial demonstrated that tafasitamab plus lenalidomide and R-CHOP significantly improved PFS outcomes in previously untreated patients with high-risk diffuse large B-cell lymphoma or high-grade B-cell...
Results from the phase 3 frontMIND trial demonstrated that tafasitamab plus lenalidomide and R-CHOP significantly improved PFS outcomes in previously untreated patients with high-risk diffuse large B-cell lymphoma or high-grade B-cell...
Results from the phase 3...
06/15/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use